A study of a new combination insulin and GLP-1 pen for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This trial tests a new combination pen (insulin degludec with liraglutide) for people with type 2 diabetes whose blood sugar is not well controlled on metformin alone or with one other pill. The goal is to see if the combination improves blood sugar control safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and live in China.
- You have type 2 diabetes for at least 6 months.
- Your most recent blood sugar test (HbA1c) is between 7.0% and 10.0%.
- You currently take metformin (at least 1500 mg daily or the highest dose you can handle) alone or with one other diabetes pill (like glipizide, repaglinide, acarbose, empagliflozin, or pioglitazone) for at least 2 months.
- You have never used insulin regularly for more than 2 weeks, and you have not used any GLP-1 or DPP-4 medicines in the last 3 months.
- You have not had a severe low blood sugar event or diabetic emergency (like ketoacidosis) in the last 6 months, and your kidney and liver function are good.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a once-daily injectable combination (iGlarLixi) helps control blood sugar better than usual care for people with type 2 diabetes who are already taking diabetes pills. It aims to find a more effective treatment option.
This trial tests an investigational drug called UBT251 for people with type 2 diabetes whose blood sugar is not well controlled despite taking metformin, either alone or with another diabetes medicine. The goal is to see if it can lower blood sugar levels more than a placebo.
This trial tests an investigational medication (HS-20094) for people with type 2 diabetes. It aims to see if it can help control blood sugar and possibly support weight loss.
This trial is testing a combination of three diabetes medicines (henagliflozin, retagliptin, and metformin) in people newly diagnosed with type 2 diabetes. The goal is to see if this triple therapy works better for controlling blood sugar compared to standard treatments.
This study tests whether a new injection that combines insulin with liraglutide works better than standard premixed insulin for people with type 2 diabetes. It aims to improve blood sugar control and simplify treatment.
This study tests a combination insulin/GLP-1 medicine (iGlarLixi) with continuous glucose monitoring to see how well it controls blood sugar in Chinese adults with type 2 diabetes. It may help those whose current pills are not working enough.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.